Advanced search
Publication Cover
Journal of Asthma Volume 58, 2021 - Issue 12
Submit an article Journal homepage
563
Views
10
CrossRef citations to date
0
Altmetric
Treatment

Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?

Mirna VerglesDepartment of Pulmonology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, Zagreb, Croatia
, MD,
Zinka MatkovićDepartment of Pulmonology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, Zagreb, Croatia
, MD, PhD,
Kristina LalićDepartment of Pulmonology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, Zagreb, Croatia
, MD,
Jasna Tekavec TrkanjecDepartment of Pulmonology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, Zagreb, Croatia
, MD, PhD &
Neven TudorićDepartment of Pulmonology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, Zagreb, CroatiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5170-8074
, MD, PhDORCID Icon
Pages 1675-1679 | Received 01 Jun 2020, Accepted 20 Sep 2020, Published online: 01 Oct 2020

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ozge Can Bostan, Emine Duran, Gulseren Tuncay, Melek Cihanbeylerden, Omer Karadag, Ebru Damadoglu, Gul Karakaya & Ali F. Kalyoncu. (2023) Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study. Journal of Asthma 60:5, pages 931-937.
Read now

Articles from other publishers (9)

Charlene Desaintjean, Kaïs Ahmad, Julie Traclet, Mathieu Gerfaud-Valentin, Cecile-Audrey Durel, Jean-Charles Glerant, Arnaud Hot, François Lestelle, Sabine Mainbourg, Mouhamad Nasser, Pascal Seve, Ségolène Turquier, Gilles Devouassoux & Vincent Cottin. (2024) Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis. Frontiers in Medicine 11.
Crossref
Eduardo Tuta-Quintero, Isabella Perna-Reyes, Juan Olivella-Gómez, Daniela Rodríguez-Fraile, Juan C. Santacruz, Andrea A. Mayorga-Borja & John Londoño. (2024) Evidencia terapéutica del mepolizumab en la granulomatosis eosinofílica con poliangeítis: una revisión exploratoria. Revista Colombiana de Reumatología.
Crossref
B. Cremonezi Lammoglia, L. De Aguiar Trevise, T. Paslar Leal, M. Pereira Lopes Vieira Pinto, G. Hasselmann & N. Salles Rosa Neto. (2023) Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission. Reumatismo 75:4.
Crossref
Diego Bagnasco, Edoardo Vincenzo Savarino, Mona-Rita Yacoub, Fulvio Braido, Maria Giulia Candeliere, Edoardo Giannini, Giovanni Passalacqua & Elisa Marabotto. (2023) Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy. Pharmaceutics 15:9, pages 2359.
Crossref
Ioannis Kouverianos, Andreas Angelopoulos & Dimitrios Daoussis. (2023) The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review. Rheumatology International 43:7, pages 1245-1252.
Crossref
Susanne Benseler. 2020. Pädiatrische Rheumatologie. Pädiatrische Rheumatologie 1 14 .
Susanne Benseler. 2022. Pädiatrische Rheumatologie. Pädiatrische Rheumatologie 683 696 .
Francesco Menzella, Carla Galeone, Giulia Ghidoni, Patrizia Ruggiero, Silvia Capobelli, Anna Simonazzi, Chiara Catellani, Chiara Scelfo, Francesco Livrieri & Nicola Facciolongo. (2021) Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab. Multidisciplinary Respiratory Medicine 16.
Crossref
. (2020) Multiple drugs. Reactions Weekly 1827:1, pages 248-248.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.